NCT03714542

Brief Summary

The precision of MRI has improved over the past few years, in particular for the hepatobiliary and pancreatic pathologies. The role of MRI in the management of operated pancreas tumors remains nevertheless unclear and few studies have compared MRI to the actual gold standard (CT). Compared to CT, MRI is not only a morphologic imaging technique but also a functional imaging technique. MRI could therefore evaluate in a non-ionizing and dynamic way several important pre- and postoperative aspects after pancreaticoduodenectomy (PD). This study on the perioperative role of MRI includes 3 parts: First, CT is known to minimize the real size of the pancreatic tumors and to underestimate the vascular invasion correlated to resectability. The preoperative determination of the resection surgical margins could be improved thanks to the high-contrast resolution of MRI. Moreover, PD is a complex surgery encompassing a fragile anastomosis between the pancreatic parenchyma and the digestive tract. The permeability of the pancreatic anastomosis after PD remains presently unknown and has not been correlated to the clinical state of the patient. MRI associated with secretin injection allows evaluating this permeability, which cannot be done by CT due to the absence of functional evaluation. Finally, present radiological follow-up after PD for tumors of the pancreatic head is performed with CT. The MRI performance has not been demonstrated yet in the context of follow-up. This imaging modality nevertheless offers unique specificities that are very interesting and that could be helpful for the diagnosis of recurrence.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2016

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 5, 2016

Completed
2.2 years until next milestone

First Posted

Study publicly available on registry

October 22, 2018

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2020

Completed
Last Updated

June 11, 2020

Status Verified

June 1, 2020

Enrollment Period

3.9 years

First QC Date

August 5, 2016

Last Update Submit

June 10, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluation of the MRI precision in the delimitation of circumferential resection margins

    The preoperative MRI results will be compared to the anatomopathological results.

    Preoperative MRI performed up to one month before the operation date.

Secondary Outcomes (6)

  • Evaluation of the potential correlation between the tumor size and the resection margins.

    Preoperative MRI performed up to one month before the operation date.

  • Determination of the pancreatic anastomosis permeability

    One year after the operation

  • Determination of the rate of exocrine insufficiency

    One year after the operation

  • Correlation between anastomosis non-permeability and exocrine insufficiency.

    One year after the operation

  • Evaluation of a questionnaire for pancreas exocrine insufficiency

    One year after the operation

  • +1 more secondary outcomes

Study Arms (1)

Pre- and postoperative MRI

OTHER

All patients will undergo a preoperative MRI and will have a postoperative follow-up with CT and MRI.

Other: Pre- and postoperative MRI

Interventions

Pre- and postoperative MRI

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients over 18 years old
  • indication for a PD for a resectable adenocarcinoma of the pancreatic head.

You may not qualify if:

  • chronic pancreatitis
  • absence of discernment
  • patients not speaking French
  • preoperative radio/chemotherapy
  • patients with claustrophobia
  • patients with metallic implants.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Lausanne Hospital

Lausanne, Canton of Vaud, 1010, Switzerland

Location

MeSH Terms

Interventions

Lead

Intervention Hierarchy (Ancestors)

Metals, HeavyElementsInorganic ChemicalsMetals

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 5, 2016

First Posted

October 22, 2018

Study Start

July 1, 2016

Primary Completion

June 1, 2020

Study Completion

June 1, 2020

Last Updated

June 11, 2020

Record last verified: 2020-06

Locations